Market Research Logo

Ipsen S.A. - Product Pipeline Review - 2016

Ipsen S.A. - Product Pipeline Review - 2016

Summary



Global Markets Direct’s, ‘Ipsen S.A. - Product Pipeline Review - 2016’, provides an overview of the Ipsen S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ipsen S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Ipsen S.A.
  • The report provides overview of Ipsen S.A. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Ipsen S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Ipsen S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Ipsen S.A.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ipsen S.A.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ipsen S.A.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Ipsen S.A. Snapshot
Ipsen S.A. Overview
Key Information
Key Facts
Ipsen S.A. - Research and Development Overview
Key Therapeutic Areas
Ipsen S.A. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Ipsen S.A. - Pipeline Products Glance
Ipsen S.A. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Ipsen S.A. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Phase 0 Products/Combination Treatment Modalities
Ipsen S.A. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Ipsen S.A. - Drug Profiles
lanreotide acetate
Product Description
Mechanism of Action
R&D Progress
abobotulinumtoxin A
Product Description
Mechanism of Action
R&D Progress
abobotulinumtoxin A next generation
Product Description
Mechanism of Action
R&D Progress
triptorelin pamoate PR
Product Description
Mechanism of Action
R&D Progress
BN-82451
Product Description
Mechanism of Action
R&D Progress
BIM-23A758
Product Description
Mechanism of Action
R&D Progress
3BP-227
Product Description
Mechanism of Action
R&D Progress
Peptides for Endocrine Gland Disorders
Product Description
Mechanism of Action
R&D Progress
Peptides for Oncology and Genito Urinary System And Sex Hormones
Product Description
Mechanism of Action
R&D Progress
Peptides to Antagonize ACTH Receptor for Cushing's Syndrome
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 1 to Inhibit SNARE for Neurology
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 1 to Target SNAP-25 for Movement Disorders
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 2 to Inhibit SNARE for Neurology
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 3 to Target SNAP-25 for Movement Disorders
Product Description
Mechanism of Action
R&D Progress
STX-140
Product Description
Mechanism of Action
R&D Progress
STX-681
Product Description
Mechanism of Action
R&D Progress
SXN-101742
Product Description
Mechanism of Action
R&D Progress
SXN-101959
Product Description
Mechanism of Action
R&D Progress
Drugs to Antagonize Androgen Receptor for Prostate Cancer
Product Description
Mechanism of Action
R&D Progress
Peptides for Endocrine Disease
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 2 to Target SNAP-25 for Movement Disorders
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 4 to Target SNAP-25 for Movement Disorders
Product Description
Mechanism of Action
R&D Progress
Ipsen S.A. - Pipeline Analysis
Ipsen S.A. - Pipeline Products by Target
Ipsen S.A. - Pipeline Products by Route of Administration
Ipsen S.A. - Pipeline Products by Molecule Type
Ipsen S.A. - Pipeline Products by Mechanism of Action
Ipsen S.A. - Recent Pipeline Updates
Ipsen S.A. - Dormant Projects
Ipsen S.A. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BIM-23A760
(mecasermin + somatropin)
irosustat
taspoglutide
Ipsen S.A. - Company Statement
Ipsen S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Ipsen S.A., Key Information
Ipsen S.A., Key Facts
Ipsen S.A. - Pipeline by Indication, 2016
Ipsen S.A. - Pipeline by Stage of Development, 2016
Ipsen S.A. - Monotherapy Products in Pipeline, 2016
Ipsen S.A. - Partnered Products in Pipeline, 2016
Ipsen S.A. - Partnered Products/ Combination Treatment Modalities, 2016
Ipsen S.A. - Out-Licensed Products in Pipeline, 2016
Ipsen S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Ipsen S.A. - Pre-Registration, 2016
Ipsen S.A. - Phase III, 2016
Ipsen S.A. - Phase II, 2016
Ipsen S.A. - Phase I, 2016
Ipsen S.A. - Phase 0, 2016
Ipsen S.A. - Preclinical, 2016
Ipsen S.A. - Discovery, 2016
Ipsen S.A. - Pipeline by Target, 2016
Ipsen S.A. - Pipeline by Route of Administration, 2016
Ipsen S.A. - Pipeline by Molecule Type, 2016
Ipsen S.A. - Pipeline Products by Mechanism of Action, 2016
Ipsen S.A. - Recent Pipeline Updates, 2016
Ipsen S.A. - Dormant Developmental Projects,2016
Ipsen S.A. - Discontinued Pipeline Products, 2016
Ipsen S.A., Subsidiaries
List of Figures
Ipsen S.A. - Pipeline by Top 10 Indication, 2016
Ipsen S.A. - Pipeline by Stage of Development, 2016
Ipsen S.A. - Monotherapy Products in Pipeline, 2016
Ipsen S.A. - Partnered Products in Pipeline, 2016
Ipsen S.A. - Out-Licensed Products in Pipeline, 2016
Ipsen S.A. - Pipeline by Top 10 Target, 2016
Ipsen S.A. - Pipeline by Route of Administration, 2016
Ipsen S.A. - Pipeline by Molecule Type, 2016
Ipsen S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report